Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Bruins Live

2

0

Final

Mass. Movers

Bank reaffirms ‘neutral’ rating on Idenix

Idenix aims to develop drugs to treat viral diseases.

Associated Press/File 2012

Idenix aims to develop drugs to treat viral diseases.

Continue reading below

Bank of America reaffirmed its “neutral” rating on shares of Cambridge-based Idenix Pharmaceuticals in a research note released Monday, according to Jags Report. The bank currently has a $7 price target, up from $6. Idenix announced a nonexclusive collaboration with Janssen Pharmaceuticals Inc. for “the clinical development of all-oral direct-acting antiviral HCV combination therapies” — in other words, drug combinations to treat infection with the hepatitis C virus.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week